Drug Trial Radar · NCT06095388
Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Actual
Start
Oct 4, 2023
Primary completion
Oct 31, 2029
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.
Conditions
- Mucopolysaccharidosis III-A
Interventions
JR-441Drug
IV infusion
JR-441Drug
IV infusion
JR-441Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the tolerability of JR-441 in MPSIIIA patientsTime frame: up to 5 years (multiple visits)
- To assess the safety of JR-441 in MPSIII-A patientsTime frame: up to 5 years (multiple visits)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.